Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare Progression Free Survival (PFS) using RECIST 1.1 as assessed by (Blinded Independent Central Review) BICR and Overall Survival (OS) in PD-L1 positive subjects and all subjects with advanced or metastatic urothelial carcinoma treated with: (a) Pembrolizumab + chemotherapy versus chemotherapy (b) Pembrolizumab versus chemotherapy
Inclusion criteria
- Advanced or Metastatic Urothelial Carcinoma